nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—Methotrexate—bone cancer	0.325	1	CrCtD
Pralatrexate—DHFR—bone cancer	0.22	1	CbGaD
Pralatrexate—SLC19A1—Methotrexate—bone cancer	0.0898	0.426	CbGbCtD
Pralatrexate—FPGS—Methotrexate—bone cancer	0.0649	0.308	CbGbCtD
Pralatrexate—Folic Acid—Methotrexate—bone cancer	0.043	0.2	CrCrCtD
Pralatrexate—Raltitrexed—Methotrexate—bone cancer	0.043	0.2	CrCrCtD
Pralatrexate—Pemetrexed—Methotrexate—bone cancer	0.043	0.2	CrCrCtD
Pralatrexate—Tetrahydrofolic acid—Methotrexate—bone cancer	0.043	0.2	CrCrCtD
Pralatrexate—Leucovorin—Methotrexate—bone cancer	0.043	0.2	CrCrCtD
Pralatrexate—DHFR—Methotrexate—bone cancer	0.033	0.156	CbGbCtD
Pralatrexate—TYMS—Methotrexate—bone cancer	0.023	0.109	CbGbCtD
Pralatrexate—SLC19A1—Metabolism of folate and pterines—DHFR—bone cancer	0.00315	0.139	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism of folate and pterines—DHFR—bone cancer	0.00268	0.118	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—FOLR1—bone cancer	0.00233	0.103	CbGpPWpGaD
Pralatrexate—TYMS—Pyrimidine metabolism—NT5C3A—bone cancer	0.00109	0.0483	CbGpPWpGaD
Pralatrexate—FPGS—Fluoropyrimidine Activity—DHFR—bone cancer	0.000946	0.0417	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—FOLR1—bone cancer	0.000827	0.0365	CbGpPWpGaD
Pralatrexate—Methotrexate—FOLR1—bone cancer	0.000765	0.465	CrCbGaD
Pralatrexate—SLC19A1—Folate Metabolism—DHFR—bone cancer	0.000639	0.0282	CbGpPWpGaD
Pralatrexate—TYMS—G1/S-Specific Transcription—DHFR—bone cancer	0.000586	0.0258	CbGpPWpGaD
Pralatrexate—Pemetrexed—DHFR—bone cancer	0.000568	0.345	CrCbGaD
Pralatrexate—Renal failure chronic—Cisplatin—bone cancer	0.00052	0.102	CcSEcCtD
Pralatrexate—SLC19A1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000512	0.0226	CbGpPWpGaD
Pralatrexate—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000436	0.0192	CbGpPWpGaD
Pralatrexate—TYMS—Nucleotide metabolism—NT5C3A—bone cancer	0.000426	0.0188	CbGpPWpGaD
Pralatrexate—TYMS—One Carbon Metabolism—DHFR—bone cancer	0.000393	0.0173	CbGpPWpGaD
Pralatrexate—TYMS—Trans-sulfuration and one carbon metabolism—DHFR—bone cancer	0.000353	0.0156	CbGpPWpGaD
Pralatrexate—TYMS—Fluoropyrimidine Activity—DHFR—bone cancer	0.000345	0.0152	CbGpPWpGaD
Pralatrexate—TYMS—E2F mediated regulation of DNA replication—DHFR—bone cancer	0.000345	0.0152	CbGpPWpGaD
Pralatrexate—Methotrexate—DHFR—bone cancer	0.000313	0.19	CrCbGaD
Pralatrexate—Tumour lysis syndrome—Methotrexate—bone cancer	0.000277	0.0541	CcSEcCtD
Pralatrexate—Tumour lysis syndrome—Epirubicin—bone cancer	0.000259	0.0507	CcSEcCtD
Pralatrexate—Tumour lysis syndrome—Doxorubicin—bone cancer	0.00024	0.0469	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000224	0.00989	CbGpPWpGaD
Pralatrexate—FPGS—Fluoropyrimidine Activity—TP53—bone cancer	0.000211	0.00932	CbGpPWpGaD
Pralatrexate—SLC19A1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.000192	0.00848	CbGpPWpGaD
Pralatrexate—TYMS—E2F transcription factor network—DHFR—bone cancer	0.000183	0.00805	CbGpPWpGaD
Pralatrexate—DHFR—E2F mediated regulation of DNA replication—RB1—bone cancer	0.000181	0.00796	CbGpPWpGaD
Pralatrexate—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.000164	0.00721	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.000159	0.007	CbGpPWpGaD
Pralatrexate—TYMS—E2F mediated regulation of DNA replication—RB1—bone cancer	0.000158	0.00694	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—NDUFA12—bone cancer	0.000151	0.00665	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—TP53—bone cancer	0.000143	0.00629	CbGpPWpGaD
Pralatrexate—Body temperature increased—Carboplatin—bone cancer	0.000135	0.0263	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—DHFR—bone cancer	0.000133	0.00584	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—NDUFA12—bone cancer	0.000128	0.00565	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—NT5C3A—bone cancer	0.000125	0.00551	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—PLAU—bone cancer	0.000116	0.00513	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—DHFR—bone cancer	0.000112	0.00492	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—ZW10—bone cancer	0.00011	0.00486	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—NT5C3A—bone cancer	0.000106	0.00468	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000102	0.00448	CbGpPWpGaD
Pralatrexate—TYMS—E2F transcription factor network—PLAU—bone cancer	0.000102	0.00448	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—ZW10—bone cancer	9.86e-05	0.00435	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—ZW10—bone cancer	9.62e-05	0.00424	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—RB1—bone cancer	9.57e-05	0.00422	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	9.56e-05	0.00421	CbGpPWpGaD
Pralatrexate—Dehydration—Cisplatin—bone cancer	9.46e-05	0.0185	CcSEcCtD
Pralatrexate—Hypokalaemia—Cisplatin—bone cancer	9.26e-05	0.0181	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—TP53—bone cancer	8.83e-05	0.00389	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	8.65e-05	0.00381	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—ZW10—bone cancer	8.6e-05	0.00379	CbGpPWpGaD
Pralatrexate—Neoplasm malignant—Epirubicin—bone cancer	8.43e-05	0.0165	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—TUBB4B—bone cancer	8.36e-05	0.00368	CbGpPWpGaD
Pralatrexate—Pancytopenia—Cisplatin—bone cancer	8.35e-05	0.0163	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—RB1—bone cancer	8.35e-05	0.00368	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	8.34e-05	0.00368	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—RB1—bone cancer	8.31e-05	0.00366	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	7.88e-05	0.00347	CbGpPWpGaD
Pralatrexate—Neoplasm malignant—Doxorubicin—bone cancer	7.8e-05	0.0152	CcSEcCtD
Pralatrexate—TYMS—Fluoropyrimidine Activity—TP53—bone cancer	7.71e-05	0.0034	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—GNA11—bone cancer	7.6e-05	0.00335	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—RFC1—bone cancer	7.58e-05	0.00334	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—EZH2—bone cancer	7.56e-05	0.00333	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TUBB4B—bone cancer	7.47e-05	0.00329	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—TUBB4B—bone cancer	7.29e-05	0.00321	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—RB1—bone cancer	7.25e-05	0.0032	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	7.17e-05	0.00316	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	7.09e-05	0.00312	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	7.08e-05	0.00312	CbGpPWpGaD
Pralatrexate—DHFR—G1/S Transition—RB1—bone cancer	6.94e-05	0.00306	CbGpPWpGaD
Pralatrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	6.83e-05	0.00301	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—RFC1—bone cancer	6.77e-05	0.00299	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDK4—bone cancer	6.73e-05	0.00296	CbGpPWpGaD
Pralatrexate—Sepsis—Methotrexate—bone cancer	6.67e-05	0.013	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—RFC1—bone cancer	6.61e-05	0.00291	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ENO2—bone cancer	6.54e-05	0.00288	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TUBB4B—bone cancer	6.52e-05	0.00287	CbGpPWpGaD
Pralatrexate—Sepsis—Epirubicin—bone cancer	6.25e-05	0.0122	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	6.18e-05	0.00273	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—DHFR—bone cancer	6.07e-05	0.00267	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—RB1—bone cancer	6.06e-05	0.00267	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	6e-05	0.00264	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—RFC1—bone cancer	5.91e-05	0.00261	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDK4—bone cancer	5.87e-05	0.00259	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—RB1—bone cancer	5.85e-05	0.00258	CbGpPWpGaD
Pralatrexate—Sepsis—Doxorubicin—bone cancer	5.78e-05	0.0113	CcSEcCtD
Pralatrexate—Anaemia—Cisplatin—bone cancer	5.66e-05	0.0111	CcSEcCtD
Pralatrexate—FPGS—Disease—ENO2—bone cancer	5.56e-05	0.00245	CbGpPWpGaD
Pralatrexate—Leukopenia—Cisplatin—bone cancer	5.48e-05	0.0107	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—ENO2—bone cancer	5.48e-05	0.00241	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NDUFA12—bone cancer	5.36e-05	0.00236	CbGpPWpGaD
Pralatrexate—Pain in extremity—Epirubicin—bone cancer	5.22e-05	0.0102	CcSEcCtD
Pralatrexate—FPGS—Disease—DHFR—bone cancer	5.16e-05	0.00227	CbGpPWpGaD
Pralatrexate—Liver function test abnormal—Methotrexate—bone cancer	5.15e-05	0.0101	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—RB1—bone cancer	5.1e-05	0.00225	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—DHFR—bone cancer	5.08e-05	0.00224	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TP53—bone cancer	5.07e-05	0.00224	CbGpPWpGaD
Pralatrexate—Toxic epidermal necrolysis—Methotrexate—bone cancer	5.03e-05	0.00982	CcSEcCtD
Pralatrexate—Oedema—Cisplatin—bone cancer	5e-05	0.00977	CcSEcCtD
Pralatrexate—Thrombocytopenia—Cisplatin—bone cancer	4.9e-05	0.00957	CcSEcCtD
Pralatrexate—Tachycardia—Cisplatin—bone cancer	4.88e-05	0.00953	CcSEcCtD
Pralatrexate—Dehydration—Epirubicin—bone cancer	4.86e-05	0.00949	CcSEcCtD
Pralatrexate—Pain in extremity—Doxorubicin—bone cancer	4.83e-05	0.00945	CcSEcCtD
Pralatrexate—Liver function test abnormal—Epirubicin—bone cancer	4.82e-05	0.00942	CcSEcCtD
Pralatrexate—Anorexia—Cisplatin—bone cancer	4.77e-05	0.00931	CcSEcCtD
Pralatrexate—Hypokalaemia—Epirubicin—bone cancer	4.75e-05	0.00929	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—GNA11—bone cancer	4.75e-05	0.00209	CbGpPWpGaD
Pralatrexate—Toxic epidermal necrolysis—Epirubicin—bone cancer	4.7e-05	0.00919	CcSEcCtD
Pralatrexate—TYMS—Metabolism—NDUFA12—bone cancer	4.68e-05	0.00206	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ENO2—bone cancer	4.66e-05	0.00205	CbGpPWpGaD
Pralatrexate—Pancytopenia—Methotrexate—bone cancer	4.58e-05	0.00895	CcSEcCtD
Pralatrexate—Neutropenia—Methotrexate—bone cancer	4.51e-05	0.00882	CcSEcCtD
Pralatrexate—Dehydration—Doxorubicin—bone cancer	4.5e-05	0.00878	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Methotrexate—bone cancer	4.48e-05	0.00876	CcSEcCtD
Pralatrexate—Liver function test abnormal—Doxorubicin—bone cancer	4.46e-05	0.00872	CcSEcCtD
Pralatrexate—Dyspnoea—Cisplatin—bone cancer	4.46e-05	0.00871	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.45e-05	0.00196	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NT5C3A—bone cancer	4.44e-05	0.00196	CbGpPWpGaD
Pralatrexate—Hypokalaemia—Doxorubicin—bone cancer	4.4e-05	0.0086	CcSEcCtD
Pralatrexate—SLC19A1—Disease—TGFBR2—bone cancer	4.4e-05	0.00194	CbGpPWpGaD
Pralatrexate—Toxic epidermal necrolysis—Doxorubicin—bone cancer	4.35e-05	0.00851	CcSEcCtD
Pralatrexate—Decreased appetite—Cisplatin—bone cancer	4.35e-05	0.00849	CcSEcCtD
Pralatrexate—FPGS—Metabolism—DHFR—bone cancer	4.32e-05	0.0019	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CYP3A4—bone cancer	4.3e-05	0.0019	CbGpPWpGaD
Pralatrexate—Pancytopenia—Epirubicin—bone cancer	4.29e-05	0.00838	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—CDK4—bone cancer	4.27e-05	0.00188	CbGpPWpGaD
Pralatrexate—Neutropenia—Epirubicin—bone cancer	4.22e-05	0.00825	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Epirubicin—bone cancer	4.2e-05	0.0082	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—DHFR—bone cancer	4.1e-05	0.00181	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—bone cancer	4.07e-05	0.00179	CbGpPWpGaD
Pralatrexate—Epistaxis—Methotrexate—bone cancer	4.06e-05	0.00793	CcSEcCtD
Pralatrexate—FPGS—Metabolism—GNA11—bone cancer	4.04e-05	0.00178	CbGpPWpGaD
Pralatrexate—Pancytopenia—Doxorubicin—bone cancer	3.97e-05	0.00775	CcSEcCtD
Pralatrexate—Body temperature increased—Cisplatin—bone cancer	3.95e-05	0.00772	CcSEcCtD
Pralatrexate—Neutropenia—Doxorubicin—bone cancer	3.91e-05	0.00763	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Doxorubicin—bone cancer	3.88e-05	0.00759	CcSEcCtD
Pralatrexate—TYMS—Metabolism—NT5C3A—bone cancer	3.87e-05	0.00171	CbGpPWpGaD
Pralatrexate—Epistaxis—Epirubicin—bone cancer	3.8e-05	0.00742	CcSEcCtD
Pralatrexate—FPGS—Disease—TGFBR2—bone cancer	3.74e-05	0.00165	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—GSTP1—bone cancer	3.68e-05	0.00162	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—DHFR—bone cancer	3.66e-05	0.00162	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CYP3A4—bone cancer	3.66e-05	0.00161	CbGpPWpGaD
Pralatrexate—Asthenia—Cisplatin—bone cancer	3.59e-05	0.00701	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—bone cancer	3.55e-05	0.00156	CbGpPWpGaD
Pralatrexate—Epistaxis—Doxorubicin—bone cancer	3.51e-05	0.00687	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—CHEK2—bone cancer	3.51e-05	0.00155	CbGpPWpGaD
Pralatrexate—Diarrhoea—Cisplatin—bone cancer	3.42e-05	0.00668	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.3e-05	0.00145	CbGpPWpGaD
Pralatrexate—Back pain—Methotrexate—bone cancer	3.25e-05	0.00635	CcSEcCtD
Pralatrexate—Vomiting—Cisplatin—bone cancer	3.18e-05	0.00621	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.18e-05	0.0014	CbGpPWpGaD
Pralatrexate—Rash—Cisplatin—bone cancer	3.15e-05	0.00616	CcSEcCtD
Pralatrexate—Dermatitis—Cisplatin—bone cancer	3.15e-05	0.00615	CcSEcCtD
Pralatrexate—FPGS—Metabolism—GSTP1—bone cancer	3.13e-05	0.00138	CbGpPWpGaD
Pralatrexate—Anaemia—Methotrexate—bone cancer	3.11e-05	0.00607	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—CHEK2—bone cancer	3.06e-05	0.00135	CbGpPWpGaD
Pralatrexate—Back pain—Epirubicin—bone cancer	3.04e-05	0.00595	CcSEcCtD
Pralatrexate—Leukopenia—Methotrexate—bone cancer	3.01e-05	0.00588	CcSEcCtD
Pralatrexate—SLC19A1—Disease—KIT—bone cancer	3e-05	0.00132	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—BRCA2—bone cancer	2.97e-05	0.00131	CbGpPWpGaD
Pralatrexate—Nausea—Cisplatin—bone cancer	2.97e-05	0.0058	CcSEcCtD
Pralatrexate—Cough—Methotrexate—bone cancer	2.93e-05	0.00573	CcSEcCtD
Pralatrexate—Anaemia—Epirubicin—bone cancer	2.91e-05	0.00568	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.87e-05	0.00126	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—BRAF—bone cancer	2.82e-05	0.00124	CbGpPWpGaD
Pralatrexate—Leukopenia—Epirubicin—bone cancer	2.82e-05	0.0055	CcSEcCtD
Pralatrexate—Back pain—Doxorubicin—bone cancer	2.82e-05	0.0055	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—JUN—bone cancer	2.75e-05	0.00121	CbGpPWpGaD
Pralatrexate—Cough—Epirubicin—bone cancer	2.75e-05	0.00536	CcSEcCtD
Pralatrexate—Anaemia—Doxorubicin—bone cancer	2.69e-05	0.00526	CcSEcCtD
Pralatrexate—Thrombocytopenia—Methotrexate—bone cancer	2.69e-05	0.00525	CcSEcCtD
Pralatrexate—Anorexia—Methotrexate—bone cancer	2.62e-05	0.00511	CcSEcCtD
Pralatrexate—Leukopenia—Doxorubicin—bone cancer	2.61e-05	0.00509	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—BRCA2—bone cancer	2.6e-05	0.00114	CbGpPWpGaD
Pralatrexate—Oedema—Epirubicin—bone cancer	2.57e-05	0.00502	CcSEcCtD
Pralatrexate—FPGS—Disease—KIT—bone cancer	2.55e-05	0.00112	CbGpPWpGaD
Pralatrexate—Cough—Doxorubicin—bone cancer	2.54e-05	0.00496	CcSEcCtD
Pralatrexate—Thrombocytopenia—Epirubicin—bone cancer	2.51e-05	0.00491	CcSEcCtD
Pralatrexate—Tachycardia—Epirubicin—bone cancer	2.51e-05	0.0049	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDK4—bone cancer	2.47e-05	0.00109	CbGpPWpGaD
Pralatrexate—Anorexia—Epirubicin—bone cancer	2.45e-05	0.00478	CcSEcCtD
Pralatrexate—Dyspnoea—Methotrexate—bone cancer	2.45e-05	0.00478	CcSEcCtD
Pralatrexate—FPGS—Disease—BRAF—bone cancer	2.4e-05	0.00106	CbGpPWpGaD
Pralatrexate—Decreased appetite—Methotrexate—bone cancer	2.39e-05	0.00466	CcSEcCtD
Pralatrexate—Oedema—Doxorubicin—bone cancer	2.38e-05	0.00464	CcSEcCtD
Pralatrexate—Fatigue—Methotrexate—bone cancer	2.37e-05	0.00462	CcSEcCtD
Pralatrexate—SLC19A1—Disease—MDM2—bone cancer	2.36e-05	0.00104	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Doxorubicin—bone cancer	2.33e-05	0.00455	CcSEcCtD
Pralatrexate—DHFR—Disease—ENO2—bone cancer	2.32e-05	0.00102	CbGpPWpGaD
Pralatrexate—Tachycardia—Doxorubicin—bone cancer	2.32e-05	0.00453	CcSEcCtD
Pralatrexate—Dyspnoea—Epirubicin—bone cancer	2.29e-05	0.00447	CcSEcCtD
Pralatrexate—SLC19A1—Disease—PTGS2—bone cancer	2.28e-05	0.001	CbGpPWpGaD
Pralatrexate—Anorexia—Doxorubicin—bone cancer	2.26e-05	0.00442	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.25e-05	0.000993	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Methotrexate—bone cancer	2.24e-05	0.00438	CcSEcCtD
Pralatrexate—Decreased appetite—Epirubicin—bone cancer	2.23e-05	0.00436	CcSEcCtD
Pralatrexate—Fatigue—Epirubicin—bone cancer	2.21e-05	0.00433	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—CDK4—bone cancer	2.21e-05	0.000972	CbGpPWpGaD
Pralatrexate—Constipation—Epirubicin—bone cancer	2.2e-05	0.00429	CcSEcCtD
Pralatrexate—Body temperature increased—Methotrexate—bone cancer	2.17e-05	0.00424	CcSEcCtD
Pralatrexate—Abdominal pain—Methotrexate—bone cancer	2.17e-05	0.00424	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDK4—bone cancer	2.15e-05	0.000949	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—RB1—bone cancer	2.15e-05	0.000945	CbGpPWpGaD
Pralatrexate—Dyspnoea—Doxorubicin—bone cancer	2.12e-05	0.00414	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Epirubicin—bone cancer	2.1e-05	0.0041	CcSEcCtD
Pralatrexate—Decreased appetite—Doxorubicin—bone cancer	2.07e-05	0.00404	CcSEcCtD
Pralatrexate—Fatigue—Doxorubicin—bone cancer	2.05e-05	0.004	CcSEcCtD
Pralatrexate—Constipation—Doxorubicin—bone cancer	2.03e-05	0.00397	CcSEcCtD
Pralatrexate—Abdominal pain—Epirubicin—bone cancer	2.03e-05	0.00397	CcSEcCtD
Pralatrexate—Body temperature increased—Epirubicin—bone cancer	2.03e-05	0.00397	CcSEcCtD
Pralatrexate—FPGS—Disease—MDM2—bone cancer	2.01e-05	0.000885	CbGpPWpGaD
Pralatrexate—Asthenia—Methotrexate—bone cancer	1.97e-05	0.00385	CcSEcCtD
Pralatrexate—DHFR—Metabolism—ENO2—bone cancer	1.94e-05	0.000857	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Doxorubicin—bone cancer	1.94e-05	0.0038	CcSEcCtD
Pralatrexate—Pruritus—Methotrexate—bone cancer	1.94e-05	0.00379	CcSEcCtD
Pralatrexate—FPGS—Disease—PTGS2—bone cancer	1.94e-05	0.000853	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDK4—bone cancer	1.92e-05	0.000848	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—RB1—bone cancer	1.92e-05	0.000845	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS2—bone cancer	1.91e-05	0.000841	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.89e-05	0.000834	CbGpPWpGaD
Pralatrexate—Abdominal pain—Doxorubicin—bone cancer	1.88e-05	0.00367	CcSEcCtD
Pralatrexate—Body temperature increased—Doxorubicin—bone cancer	1.88e-05	0.00367	CcSEcCtD
Pralatrexate—Diarrhoea—Methotrexate—bone cancer	1.88e-05	0.00367	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—RB1—bone cancer	1.87e-05	0.000825	CbGpPWpGaD
Pralatrexate—Asthenia—Epirubicin—bone cancer	1.84e-05	0.0036	CcSEcCtD
Pralatrexate—Pruritus—Epirubicin—bone cancer	1.82e-05	0.00355	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—bone cancer	1.82e-05	0.0008	CbGpPWpGaD
Pralatrexate—Diarrhoea—Epirubicin—bone cancer	1.76e-05	0.00343	CcSEcCtD
Pralatrexate—Vomiting—Methotrexate—bone cancer	1.74e-05	0.00341	CcSEcCtD
Pralatrexate—Rash—Methotrexate—bone cancer	1.73e-05	0.00338	CcSEcCtD
Pralatrexate—Dermatitis—Methotrexate—bone cancer	1.73e-05	0.00338	CcSEcCtD
Pralatrexate—Asthenia—Doxorubicin—bone cancer	1.7e-05	0.00333	CcSEcCtD
Pralatrexate—TYMS—Metabolism—ENO2—bone cancer	1.7e-05	0.000748	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GNA11—bone cancer	1.69e-05	0.000743	CbGpPWpGaD
Pralatrexate—Pruritus—Doxorubicin—bone cancer	1.68e-05	0.00328	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—RB1—bone cancer	1.67e-05	0.000738	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MDM2—bone cancer	1.64e-05	0.000721	CbGpPWpGaD
Pralatrexate—Vomiting—Epirubicin—bone cancer	1.63e-05	0.00319	CcSEcCtD
Pralatrexate—Nausea—Methotrexate—bone cancer	1.63e-05	0.00318	CcSEcCtD
Pralatrexate—Diarrhoea—Doxorubicin—bone cancer	1.63e-05	0.00318	CcSEcCtD
Pralatrexate—FPGS—Metabolism—PTGS2—bone cancer	1.62e-05	0.000715	CbGpPWpGaD
Pralatrexate—Rash—Epirubicin—bone cancer	1.62e-05	0.00316	CcSEcCtD
Pralatrexate—Dermatitis—Epirubicin—bone cancer	1.62e-05	0.00316	CcSEcCtD
Pralatrexate—SLC19A1—Disease—EGFR—bone cancer	1.61e-05	0.000711	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—DHFR—bone cancer	1.57e-05	0.000694	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TGFBR2—bone cancer	1.56e-05	0.000688	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP3A4—bone cancer	1.53e-05	0.000674	CbGpPWpGaD
Pralatrexate—Nausea—Epirubicin—bone cancer	1.53e-05	0.00298	CcSEcCtD
Pralatrexate—Vomiting—Doxorubicin—bone cancer	1.51e-05	0.00295	CcSEcCtD
Pralatrexate—Rash—Doxorubicin—bone cancer	1.5e-05	0.00293	CcSEcCtD
Pralatrexate—Dermatitis—Doxorubicin—bone cancer	1.5e-05	0.00292	CcSEcCtD
Pralatrexate—TYMS—Metabolism—GNA11—bone cancer	1.47e-05	0.000648	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MDM2—bone cancer	1.43e-05	0.000629	CbGpPWpGaD
Pralatrexate—Nausea—Doxorubicin—bone cancer	1.41e-05	0.00276	CcSEcCtD
Pralatrexate—FPGS—Disease—EGFR—bone cancer	1.37e-05	0.000605	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP3A4—bone cancer	1.33e-05	0.000588	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTP1—bone cancer	1.31e-05	0.000576	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTP1—bone cancer	1.14e-05	0.000503	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KIT—bone cancer	1.07e-05	0.00047	CbGpPWpGaD
Pralatrexate—DHFR—Disease—BRAF—bone cancer	1e-05	0.000441	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—bone cancer	9.38e-06	0.000414	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MDM2—bone cancer	8.39e-06	0.00037	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—bone cancer	8.19e-06	0.000361	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTGS2—bone cancer	8.09e-06	0.000356	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS2—bone cancer	6.77e-06	0.000299	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS2—bone cancer	5.91e-06	0.00026	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGFR—bone cancer	5.73e-06	0.000253	CbGpPWpGaD
